JP2022512735A - 肝疾患を治療するための組成物および方法 - Google Patents

肝疾患を治療するための組成物および方法 Download PDF

Info

Publication number
JP2022512735A
JP2022512735A JP2021521144A JP2021521144A JP2022512735A JP 2022512735 A JP2022512735 A JP 2022512735A JP 2021521144 A JP2021521144 A JP 2021521144A JP 2021521144 A JP2021521144 A JP 2021521144A JP 2022512735 A JP2022512735 A JP 2022512735A
Authority
JP
Japan
Prior art keywords
wisp1
antibody
liver
liver disease
mir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021521144A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512735A5 (enExample
Inventor
ユンソク チェ，マイケル
Original Assignee
ザ ジェネラル ホスピタル コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ジェネラル ホスピタル コーポレイション filed Critical ザ ジェネラル ホスピタル コーポレイション
Publication of JP2022512735A publication Critical patent/JP2022512735A/ja
Publication of JP2022512735A5 publication Critical patent/JP2022512735A5/ja
Priority to JP2024163238A priority Critical patent/JP2025011102A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
JP2021521144A 2018-10-19 2019-10-18 肝疾患を治療するための組成物および方法 Withdrawn JP2022512735A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024163238A JP2025011102A (ja) 2018-10-19 2024-09-20 肝疾患を治療するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862747903P 2018-10-19 2018-10-19
US62/747,903 2018-10-19
PCT/US2019/056910 WO2020081920A1 (en) 2018-10-19 2019-10-18 Compositions and methods for treatment of liver disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024163238A Division JP2025011102A (ja) 2018-10-19 2024-09-20 肝疾患を治療するための組成物および方法

Publications (2)

Publication Number Publication Date
JP2022512735A true JP2022512735A (ja) 2022-02-07
JP2022512735A5 JP2022512735A5 (enExample) 2022-10-25

Family

ID=70284106

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021521144A Withdrawn JP2022512735A (ja) 2018-10-19 2019-10-18 肝疾患を治療するための組成物および方法
JP2024163238A Pending JP2025011102A (ja) 2018-10-19 2024-09-20 肝疾患を治療するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024163238A Pending JP2025011102A (ja) 2018-10-19 2024-09-20 肝疾患を治療するための組成物および方法

Country Status (9)

Country Link
US (2) US20210388073A1 (enExample)
EP (1) EP3866852A4 (enExample)
JP (2) JP2022512735A (enExample)
KR (1) KR20210081366A (enExample)
CN (2) CN120305401A (enExample)
AU (1) AU2019361120A1 (enExample)
CA (1) CA3117098A1 (enExample)
IL (1) IL282251A (enExample)
WO (1) WO2020081920A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA129546C2 (uk) 2019-09-16 2025-05-28 Опсідіо, Ллк Антитіла проти фактора стовбурових клітин і способи їх застосування
US20220378843A1 (en) * 2019-11-01 2022-12-01 Figene, Llc Fibroblast-based therapy for treatment of sclerosing cholangitis
CN117487010B (zh) * 2022-08-02 2025-02-14 东莞市朋志生物科技有限公司 抗四碘甲状腺素抗体或其功能性片段、检测四碘甲状腺素的试剂和试剂盒
CN120813600A (zh) * 2023-03-03 2025-10-17 无限生物制药公司 抗体或其抗原结合片段
CN117045680B (zh) * 2023-10-12 2023-12-08 北京国卫生物科技有限公司 促进肝脏再生的干细胞制剂及其制备方法
WO2025179048A2 (en) * 2024-02-20 2025-08-28 Ecogenome Llc Antibodies that bind dach1 and methods of use
CN119331100B (zh) * 2024-10-16 2025-07-25 天津大学 特异性结合25-羟基维生素d的单克隆抗体及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000064478A1 (en) * 1999-04-27 2000-11-02 Mitsubishi Pharma Corporation Preventives/remedies for liver diseases
WO2003014345A1 (fr) * 2001-08-08 2003-02-20 Ajinomoto Co., Inc. Ensemble de genes participant a l'activation des astrocytes du foie
JP2013531487A (ja) * 2010-06-02 2013-08-08 アルナイラム ファーマシューティカルズ， インコーポレイテッド 肝線維症治療用組成物および肝線維症の治療法
JP2017513854A (ja) * 2014-04-15 2017-06-01 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｗｉｓｐ１に結合する抗原結合タンパク質
WO2017201422A1 (en) * 2016-05-20 2017-11-23 The General Hospital Corporation Using micrornas to control activation status of hepatic stellate cells and to prevent fibrosis in progressive liver diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387657B1 (en) * 1997-10-29 2002-05-14 Genentech, Inc. WISP polypeptides and nucleic acids encoding same
EP3229586B1 (en) * 2014-12-10 2025-07-30 Regents of the University of Minnesota Genetically modified cells, tissues, and organs for treating disease

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000064478A1 (en) * 1999-04-27 2000-11-02 Mitsubishi Pharma Corporation Preventives/remedies for liver diseases
WO2003014345A1 (fr) * 2001-08-08 2003-02-20 Ajinomoto Co., Inc. Ensemble de genes participant a l'activation des astrocytes du foie
JP2013531487A (ja) * 2010-06-02 2013-08-08 アルナイラム ファーマシューティカルズ， インコーポレイテッド 肝線維症治療用組成物および肝線維症の治療法
JP2017513854A (ja) * 2014-04-15 2017-06-01 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｗｉｓｐ１に結合する抗原結合タンパク質
WO2017201422A1 (en) * 2016-05-20 2017-11-23 The General Hospital Corporation Using micrornas to control activation status of hepatic stellate cells and to prevent fibrosis in progressive liver diseases

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ARCH. MED. SCI., vol. 11, no. 3, JPN6023038722, 2015, pages 647 - 653, ISSN: 0005327300 *
JOURNAL OF HEPATOLOGY, vol. 68, no. 1, JPN6023038723, April 2018 (2018-04-01), pages 614 - 615, ISSN: 0005158741 *
肝胆膵, vol. 53（3）, JPN6024018745, 2006, pages 349 - 355, ISSN: 0005327303 *
肝胆膵, vol. 57(2), JPN6024018743, 2008, pages 259 - 267, ISSN: 0005327301 *
肝胆膵, vol. 60(6), JPN6024018744, 2010, pages 1033 - 1040, ISSN: 0005327302 *

Also Published As

Publication number Publication date
US20210388073A1 (en) 2021-12-16
CN113271971A (zh) 2021-08-17
EP3866852A1 (en) 2021-08-25
CN120305401A (zh) 2025-07-15
EP3866852A4 (en) 2022-07-06
AU2019361120A1 (en) 2021-05-13
US20250223344A1 (en) 2025-07-10
CA3117098A1 (en) 2020-04-23
WO2020081920A1 (en) 2020-04-23
JP2025011102A (ja) 2025-01-23
KR20210081366A (ko) 2021-07-01
IL282251A (en) 2021-05-31

Similar Documents

Publication Publication Date Title
US20250223344A1 (en) Compositions and Methods for Treatment of Liver Disease
US20240002488A1 (en) Method of treating or preventing liver conditions
KR20170080604A (ko) 항-인터류킨-33 항체 및 그것의 용도
JP6633029B2 (ja) 血管新生障害の処置
AU2018364630A1 (en) Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
KR20210142638A (ko) Cd3 항원 결합 단편 및 이의 응용
EP2882456B1 (en) Use of il-20 antagonists for treating liver diseases
US20260116986A1 (en) Epo receptor agonists and antagonists
EP1661582A1 (en) Cancer metastasis inhibitor
TWI654996B (zh) 微核糖核酸let-7及轉形生長因子β第三類受體調控軸作為心臟損傷標的之用途
JP2024540595A (ja) 強皮症疾患の治療方法
US20230416375A1 (en) Antibody variants against wnt receptor ryk
US20260035468A1 (en) New anti-itgb8 antibodies and its uses thereof
US20250326831A1 (en) Methods for treating disease using psmp antagonists
CN117751141A (zh) 用于预防或治疗癌症的抗cd300c单克隆抗体及其生物标志物
WO2016172082A1 (en) A therapeutic gene cocktail for heart regeneration
SE2350695A1 (en) Binding agents
BR112020006860A2 (pt) composição para depleção de células t citotóxicas

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221017

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221017

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230926

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240920

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241101

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20241125